Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.
Hall MS, Teer JK, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M, Nagle L, Scott E, Schachner B, Innamarato P, Hall AM, Blauvelt J, Rich CJ, Richards AD, Ceccarelli J, Langer TJ, Yoder SJ, Beatty MS, Cox CA, Messina JL, Abate-Daga D, Mule JJ, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Hall MS, et al. Among authors: beatty ms. J Immunother Cancer. 2023 Oct;11(10):e007288. doi: 10.1136/jitc-2023-007288. J Immunother Cancer. 2023. PMID: 37802604 Free PMC article.
Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.
Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Poch M, et al. Oncoimmunology. 2018 Jul 23;7(9):e1476816. doi: 10.1080/2162402X.2018.1476816. eCollection 2018. Oncoimmunology. 2018. PMID: 30228944 Free PMC article.
Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.
Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S. Aydin AM, et al. Int Immunopharmacol. 2021 May;94:107481. doi: 10.1016/j.intimp.2021.107481. Epub 2021 Feb 23. Int Immunopharmacol. 2021. PMID: 33636562 Free PMC article.
Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis.
Oshrine B, Innamarato P, Branthoover H, Nagle L, Verdugo P, Pilon-Thomas S, Beatty M. Oshrine B, et al. Transplant Cell Ther. 2022 Apr;28(4):203.e1-203.e7. doi: 10.1016/j.jtct.2021.12.019. Epub 2022 Jan 5. Transplant Cell Ther. 2022. PMID: 34995816 Free article.
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colón Colón M, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mulé JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA. Hall MS, et al. Among authors: beatty ms. Clin Cancer Res. 2022 Dec 15;28(24):5317-5329. doi: 10.1158/1078-0432.CCR-22-2103. Clin Cancer Res. 2022. PMID: 36215121 Free PMC article. Clinical Trial.
24 results